IPI-145 and ABT-199 for Lymphoid Malignancies

July 8, 2014
Anas Younes, MD

Special Reports, Hematologic Malignancies, Volume 1, Issue 1

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Learn more about inhibiting BCL-2 > >